Vikas Sinha has sold stock and made no open-market buys since Feb 2016

Vikas Sinha is the Chief Financial Officer (CFO) of Scholar Rock Holding Corporation (SRRK), a late-stage biopharmaceutical company focused on neuromuscular diseases.( With over 30 years of experience in executive finance roles within the life sciences industry, he recently engaged in insider trading at SRRK.(

Sinha is a co-founder of ElevateBio, where he previously served as CFO and now sits on the Board of Directors as Chair of the Audit Committee; he also held roles as President and CFO of AlloVir, an ElevateBio portfolio company, until March 2025.( Earlier, he was CFO of Alexion Pharmaceuticals for 11 years (2005-2016), driving market cap growth from $600 million to over $30 billion and revenue from zero to more than $3 billion.( Prior roles include VP and CFO positions at Bayer AG in the US, Japan, Germany, and Canada.( He serves on the boards of Verona Pharma (since 2016, Audit Committee Chair), Orna Therapeutics, and ElevateBio.( Sinha holds an MBA from the Asian Institute of Management (1992-1994), is a qualified Chartered Accountant (Institute of Chartered Accountants of India), and a Certified Public Accountant in the US.(

Written by Perplexity from public sources.